Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 91 points (-0.6%) at 15,838 as of Wednesday, Jan. 29, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 929 issues advancing vs. 2,026 declining with 145 unchanged. The Drugs industry currently sits down 0.5% versus the S&P 500, which is down 0.4%. A company within the industry that increased today was Medivation ( MDVN), up 12.2%. On the negative front, top decliners within the industry include GlaxoSmithKline ( GSK), down 1.9%, Sanofi ( SNY), down 1.3% and Novo Nordisk A/S ( NVO), down 1.1%. TheStreet would like to highlight 5 stocks pushing the industry higher today: 5. Vertex Pharmaceuticals ( VRTX) is one of the companies pushing the Drugs industry higher today. As of noon trading, Vertex Pharmaceuticals is up $1.44 (1.8%) to $80.74 on average volume. Thus far, 730,773 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $77.85-$81.08 after having opened the day at $78.56 as compared to the previous trading day's close of $79.30. Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Vertex Pharmaceuticals has a market cap of $18.6 billion and is part of the health care sector. Shares are up 6.7% year-to-date as of the close of trading on Tuesday. Currently there are 13 analysts who rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold. TheStreet Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Vertex Pharmaceuticals Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.